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ABSTRACT
Background Formalin-ﬁxed prostate biopsies are
frequently the only tissue collected at the time of
prostate cancer diagnosis. There is therefore
a requirement for techniques that allow the use of these
prostate biopsy specimens in a high-throughput analysis
of immunohistochemical and ﬂuorescence-in-situ-
hybridisation-detected biomarkers.
Methods The authors have previously described
methods that allow tissue microarray (TMA) construction
from prostate biopsies. Here, we describe signiﬁcant
technical innovations that provide an easier and more
robust system of biopsyeTMA construction.
Results and discussion The TMAs produced are of
a high density (up to 104 cores each, 8313) and allow
a multiplex analysis of biomarkers in the context of
clinical trials.
BACKGROUND
Although prostate cancer is a common disease (over
500000 cases are diagnosed in North America and
Europe each year), there is considerable variation in
its natural history.
1 Many cancers are indolent and
will never become life threatening while other
cases, with an initially similar appearance, may
rapidly become life threatening. Unfortunately,
established prognostic factors (Gleason score, T
stage, blood prostate-speciﬁc antigen, cancer
volume) are inadequate, and it is important to
identify new biomarkers that can predict more
precisely the clinical behaviour of individual
patients. We have previously reported methods that
can be used to test biomarkers in formalin-ﬁxed
needle biopsies taken from patients with prostate
cancer at the time of diagnosis. In each method, we
reorientate the biopsies into a vertical orientation
allowing construction of biopsy TMAs and subse-
quent analysis of the markers in cross-sections
taken from each biopsy TMA. In our original
technique, a maximum of 20 biopsy specimens
could be included within each TMA.
2 A particular
problem with this method is that the cutting out of
small regular ‘checkers’ of wax containing
a segment of the biopsy on one face, which is
required for the construction of the biopsy TMA, is
technically demanding and time-consuming. To
address this problem, we recently presented
a simpliﬁed technique for cutting wax checkers
that allowed construction of biopsy TMAs
containing 54e72 checkers.
3 The technique can be
used to examine both IHC and FISH based
biomarkers.
3 These approaches have been validated
in studies of the biomarker Ki67 in biopsy speci-
mens from active surveillance patients,
4 for the
biomarkers Hif-1a, VEGF, osteopontin, MDM2, p53
and Bcl-2 in biopsy specimens from radiotherapy
patients.
56Here, we present substantial improve-
ments of this procedure that allows more rapid
construction of TMAs containing up to 104 biopsy
cores.
TECHNICAL DEVELOPMENT
Prostate biopsy samples for these studies were
collected from men with untreated, localised (clin-
ical stage T1/2a, Gleason score #3+4; prostate-
speciﬁc antigen <15; #50% positive cores) prostate
cancer who were managed in a prospective active
surveillance study at the Royal Marsden Hospital
NHS Foundation Trust. The methods for selecting
samples for biopsy TMA construction from
patients with prostate cancer entered into active
surveillance have been described previously.
4 All
patients gave their written consent to take part in
the active surveillance study, which was approved
by the local research ethics committee.
The new procedure consists of two steps. In the
ﬁrst step, biopsy donor blocks were constructed
using previously reported methods,
2 but with only
ﬁve biopsy checkers per block (ﬁgure 1AeF). The
height of the ‘checker’ was speciﬁcally kept at
around 4 mm (ﬁgure 1A,B) as previously reported.
3
A variation in the new procedure was that the end
of the core was painted with a red dot to identify
the core end after embedding (ﬁgure 1C), and the
side of the checker opposing the biopsy core was
painted blue (ﬁgure 1D) for orientation. A ﬁnished
biopsy ‘checker’ (ﬁgure 1E) and donor block (after
parafﬁn wax embedding) (ﬁgure 1F) are shown.
In the second step, we use the conventional
TMA construction techniques described by
Kononen et al
7 to punch out the needle biopsies
from the donor block and reset them in a recipient
wax block. A hollow needle punch was pushed into
the donor block using an MTA1 Manual Tissue
Arrayer (Beecher Instruments, Silver Spring,
Maryland), to produce a 1.5 mm diameter core
with 4 mm depth (ﬁgure 2A) that encompassed
a biopsy specimen: the red marker dot (ﬁgure 1F)
was used in each case to deﬁne the position that
was punched. Each donor core was then transferred
toa 1.5 mmdiameter,4 mmdeepholethat hadbeen
punched into a recipient wax block (ﬁgure 2B). In
total, a maximum of 104 cores (8313) could be
arrayed in each recipient block. Usually a number of
blank spaces were left in each recipient block
deﬁning a unique pattern for block identiﬁcation.
This transfer procedure was usually highly efﬁcient:
a detailed examination of the many of the donor
blocks following transfer failed to identify residual
tissue. The only problems encountered were with
very curved biopsies specimens that were not
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Short reportFigure 1 Construction of biopsy donor blocks. For clarity, the formalin-ﬁxed prostate cancer needle biopsy has been coloured green. A malignant
portion of the biopsy was marked and represented here by a black rectangle (A). The biopsy was then cut from its original block with a longitudinal
length of about 4 mm to create a ‘checker’ (B). The cancerous end of the biopsy ‘checker’ was coloured red (C), and the opposing side to the biopsy
was coloured blue (D) for orientation. A ﬁnished checker (E) and donor block after embedding (F) are pictured.
Figure 2 Biopsy tissue microarray (TMA) construction.
An MTA1 manual tissue arrayer was used to punch out
a biopsy core from a donor block (A). The biopsy core
was then transferred to a recipient wax block (B). (C)
Example of a ﬁnished biopsy TMA with (D) corresponding
H&E. A black cross denotes the position of blank spaces.
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Short reportsuitable for arraying using this procedure. Preparation and
sectioning of biopsy TMA blocks were carried out exactly as
described previously.
2 An example biopsy TMA block
constructed by this method is shown in ﬁgure 2C, and the
corresponding H&E section is shown in ﬁgure 2D. The method
was initially used to construct biopsy TMAs in a 1338 format
(104 cores), but this created brittle block edges, and we consider
the 91 (1337) pattern to represent the most robust format. We
have now usedthis procedure to construct 12 TMAs from around
1000 biopsies selected from Active Surveillance and MRC RT01
Radiotherapy trials
4e6 including the coring and resetting of all
biopsies in low-density TMAs constructed using our original
method.
2
DISCUSSION
If biomarkers are to be used clinically for stratifying prostate
cancer, they must be tested and validated in tissue obtained from
the patient at the time of diagnosis, which usually just includes
transrectal-ultrasound-guided prostate needle biopsy, blood or
urine. Examination of the prostate biopsy samples yields valu-
able information including Gleason grade and extent of disease,
which facilitate decision-making on the appropriate treatment.
The platform that we have developed additionally allows the
use of formalin-ﬁxed needle biopsies in multiplex analysis of
biomarkers in the precise setting in which they would be used
clinically. The multiplex analysis of biomarkers is critical because
it is probable that a combination of biomarkers, rather than
a single biomarker, will provide the best prognostic or diagnostic
information.
8 Needle biopsies are also taken at the time of
diagnosis from many other human malignancies, including oral
cancer, breast cancer and lymph-node metastases, so the tech-
niques developed here for prostate cancer may also have rele-
vance to other diseases.
9e11 In conclusion, the improved strategy
for biopsyeTMA construction reported here represents a rapid
and robust method for producing high-density biopsyeTMA
construction that can be used to assess biomarkers in the
context of clinical trials.
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Take-home messages
< There is an urgent need to identify new biomarkers that will
aid in improved targeting of radical treatments in patients with
prostate cancer.
< To identify such biomarkers, it is essential to perform tests on
samples taken from the patient at the time of diagnosis, which
usually only include blood, urine and transultrasound-guided
prostate needle biopsy samples.
< A novel method is presented that allows the production of
high-density tissue microarrays from needle biopsies taken
from the prostate at the time of cancer diagnosis.
< The biopsy TMAs produced can be used for the multiplex
analysis of potential biomarkers detected by immunohisto-
chemistry or by ﬂuorescence in situ hybridisation in prostate
needle biopsies taken from patients entered into clinical trials.
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